摘要
目的探讨支气管肺炎患者采取布地奈德与异丙托溴铵联合治疗的临床效果。方法抽取本院接诊的支气管肺炎患者60例进行研究,入院后皆签署知情同意书愿意配合本次研究,随机均分为两组,各30例。对照组患者实施常规治疗,研究组患者在对照组治疗基础上加用布地奈德与异丙托溴铵联合治疗,对比分析两组患者临床效果,以及咳嗽、细湿罗音与气促等症状改善时间。结果研究组临床总有效显著高于对照组,同时咳嗽、细湿啰音与气促等症状改善时间均显著低于对照组,组间比较差异均有统计学意义(P<0.05或P<0.01)。结论支气管肺炎患者实施布地奈德与异丙托溴铵联合治疗,可取得比较良好的效果,疗效确切,同时患者临床症状改善更快,有很高的临床价值,值得借鉴。
Objective To explore the clinical value of budesonide combined with ipratropium in the treatment of patients with bronchopneumonia. Methods 60 patients with bronchopneumonia who were admitted to our hospital were selected as research subjects and they all signed informed consent form to cooperate in this research.Patients were randomly allocated to the research group and the control group,with 30 in each.Patients in the control group were received routine treatment while patients in the research group were received combine treatment of budesonide combined with ipratropium on a basis of treatment in the control group.Clinical effects and symptom improved time including coughing,fine and moist rale sounds,anhelation et al.Of two groups were compared. Results The clinical total effective rate of the research group was significantly higher than that of the control group.In addition,symptom improved time including coughing,fine and moist rale sounds,anhelation et al.Of the research group were all significantly shorter than those in the control group.Differences of compared groups have statistically significance（P〈0.05 or P〈0.01）. Conclusion The combined treatment of budesonide and ipratropium of patients with bronchopneumonia has a better and accurate curative effect and a shorter symptom improved time which has a very high clinical value,worthy of learning.
出处
《中国医药科学》
2015年第17期104-106,共3页
China Medicine And Pharmacy
